EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This phase II trial is studying how well EF5 works in finding oxygen in tumor cells of patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer. Diagnostic procedures using the drug EF5 to find oxygen in tumor cells may help in planning cancer treatment

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Histologically confirmed* diagnosis of 1 of the following:

• Cervical cancer

• Ovarian epithelial cancer

• Endometrial cancer

• Peritoneal cavity cancer

• Requires surgery or biopsy for diagnosis or as standard initial treatment for the tumor

• Performance status - ECOG 0-2

• WBC ≥ 2,000/mm^3

• Platelet count ≥ 100,000/mm^3

• Bilirubin normal

• Creatinine normal

• Creatinine clearance ≥ 60 mL/min

• No significant cardiac condition that would preclude study participation

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 1 month after study participation

• Weight ≤ 130 kg

• No other significant medical condition that would preclude study participation

• No scheduled chemotherapy for the tumor within the past 3 months

• No scheduled radiotherapy to the tumor within the past 3 months

• No other concurrent investigational agents